NATIVE GENE THERAPY
Dead / Abandoned — Abandoned — failure to respond (as of 15 Jun 2023)
What this means for you
This application is over — abandoned 02 Jun 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97079718
- Mark type
- Stylized text
- Filed
- 18 Oct 2021
- Abandoned
- 02 Jun 2023
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical agents that target DNA structure to treat various diseases, namely, monogenic diseases, cancer, infectious disease, immune disease, hematological conditions, haploinsufficiencies, hepatic disease, channelopathies, endocrine disease, cardiovascular disease, reproductive disease, renal disease, skeletal muscle disease, bone disease
Owner
- Omega Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 15 Jun 2023 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 15 Jun 2023 — ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
- 15 Jun 2023 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 01 Dec 2022 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 01 Dec 2022 — FINAL REFUSAL E-MAILED
- 01 Dec 2022 — FINAL REFUSAL WRITTEN
- 18 Oct 2022 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 17 Oct 2022 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 17 Oct 2022 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 17 Apr 2022 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 17 Apr 2022 — NON-FINAL ACTION E-MAILED
- 17 Apr 2022 — NON-FINAL ACTION WRITTEN
- 08 Mar 2022 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 07 Mar 2022 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 07 Mar 2022 — TEAS RESPONSE TO OFFICE ACTION RECEIVED